Market Closed -
Nasdaq
01:30:00 16/05/2024 am IST
5-day change
1st Jan Change
8.87
USD
+13.43%
+23.88%
-21.16%
This article is reserved for members
Not a member ?
Free registration
Transcript : Altimmune, Inc., Q1 2024 Earnings Call, May 09, 2024
09/05
Earnings Flash (ALT) ALTIMMUNE Reports Q1 Revenue $5,000
09/05
MT
Altimmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
09/05
CI
North American Morning Briefing : More Earnings -2-
30/04
DJ
Altimmune Shares Decline After Guggenheim Downgrade
29/04
MT
Guggenheim Downgrades Altimmune to Neutral From Buy
29/04
MT
Transcript : Altimmune, Inc. - Special Call
02/04
Altimmune Shares Slip Wednesday, After Reporting a Wider Q4 Net Loss and Dropping Prospective Treatment for Hepatitis B
27/03
MT
Transcript : Altimmune, Inc., Q4 2023 Earnings Call, Mar 27, 2024
27/03
Altimmune, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
27/03
CI
Earnings Flash (ALT) ALTIMMUNE Reports Q4 Revenue $37,000
27/03
MT
Altimmune, Inc. Announces Impairment Loss for the Three Months Ended December 31, 2023
27/03
CI
North American Morning Briefing : Stocks Edge -2-
27/03
DJ
North American Morning Briefing : Stock Futures -2-
19/03
DJ
Altimmune, Inc.(NasdaqGM:ALT) added to S&P Biotechnology Select Industry Index
18/03
CI
North American Morning Briefing : Inflation Data -2-
12/03
DJ
Drugmakers deepen efforts to tap into booming market for obesity drugs
27/02
RE
Zealand shares surge on liver drug data from Boehringer pact
26/02
RE
Altimmune shares slide after Kerrisdale Capital takes short position
13/02
RE
B. Riley Raises Altimmune's PT to $20 From $15 on Increased Obesity+NASH Therapeutics' Product Sales Projections; Keeps Buy Rating
17/01
MT
Weight loss drug windfall attracts pharma companies
11/01
RE
Drugmakers plot way into obesity market with deals and development
11/01
RE
Altimmune, Inc.(NasdaqGM:ALT) dropped from NASDAQ Biotechnology Index
15/12
CI
Social Buzz: Wallstreetbets Stocks Mostly Up Premarket; Altimmune Poised to Rise, Robinhood Markets to Decline
07/12
MT
Altimmune open to partnerships, deals with drugmakers, says CEO
05/12
RE
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Companyâs wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.
More about the company
Last Close Price
8.87
USD
Average target price
20.71
USD
Spread / Average Target
+133.53%
Consensus
1st Jan change
Capi.
-21.16% 63Cr +7.52% 11TCr +11.38% 11TCr -12.64% 2.22TCr +0.32% 2.23TCr -3.99% 1.94TCr -37.85% 1.79TCr -8.58% 1.72TCr +37.41% 1.25TCr -23.95% 834.13Cr
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
marketscreener.com**derivatives**en**/dynamic-chart/**Premium**Expert**Access**Annual**Monthly**
-40% Limited Time Offer : Our subscriptions help you unlock hidden opportunities.**#000000**/services/solutions/**#fff826**#ff3000**#ffffff**
BENEFIT NOW **0**linear-gradient(180deg, rgba(42,73,76,1) 0%, rgba(28,30,51,1) 53%);**linear-gradient(180deg, rgba(255, 248, 38,1) 0%, rgba(247, 239,1) 53%);**date_fin_hors_prolongation**49**on all our subscriptions**
#252525**/registration/member/**Blanc**1**7**To continue browsing, please register!**#ffffff50**14px**#33d251**